Prostate Cancer

Tanya B. Dorff, MD, FASCO, shares phase 1 data on ABBV-969, an investigational antibody-drug conjugate being explored for metastatic castration-resistant prostate cancer.

Kim Chi, MD, highlights findings from a pre-planned analysis of the PLUDO trial examining the impact of crossover on survival outcomes between 177Lu-PSMA-617 vs docetaxel in mCRPC.

"Compared to placebo [plus] ADT, apalutamide [plus] ADT showed 9 times more pCR/MRD, a 20% improved MFS, a 29% reduction in prostate cancer recurrence, and a 3-year improvement in time to subsequent therapy," said Mary-Ellen Taplin, MD, FASCO.

Alicia K. Morgans, MD, MPH, discusses key findings from the ARACOG study, assessing cognitive outcomes between patients who received darolutamide vs those who received enzalutamide for advanced prostate cancer.

The phase 2 ARACOG trial noted a greater decline in objectively measured cognitive function over 24 weeks among patients who received enzalutamide vs darolutamide for advanced prostate cancer.

"There is some evidence here, supported by our statistical analysis plan, that the classifier predicted the postulated benefits of adding docetaxel to ADT and enzalutamide," said Christopher Sweeney, MBBS, DHS.

In this episode of The UroOnc Minute, host Adam B. Weiner, MD, speaks with Hashim U. Ahmed, BM BCh (Oxon), about patient selection, imaging, and the future direction of focal therapy for localized prostate cancer.

Patients in the enzalutamide combination group were most likely to achieve a treatment suspension lasting a least 2 years.

Extended follow-up data from a phase 3 randomized trial show that aglatimagene besadenovec plus valacyclovir combined with radiotherapy produced a 39% improvement in prostate cancer-specific disease-free survival vs placebo plus standard-of-care radiotherapy in men with intermediate- to high-risk localized prostate cancer.

Darolutamide plus ADT also significantly delayed time to mCRPC (HR 0.26; 95% CI 0.18–0.38; P <.001) and rPFS (HR 0.30; 95% CI 0.19–0.48; P <.001) vs ADT.

A comprehensive guide to the practice-changing, paradigm-shifting studies across urologic oncology.

In a multisite validation study, the urine-based MPS2-AS assay outperformed mpMRI for detecting disease upgrading in men with GG1 prostate cancer on active surveillance and could reduce unnecessary biopsies.

The FDA Oncologic Drugs Advisory Committee voted 7-1-1 in support of a favorable risk-benefit profile for capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC.

Findings from the HIFI-2 study suggest that salvage HIFU provides meaningful mid-term oncologic control with an acceptable safety profile in patients with localized prostate cancer recurrence after radiotherapy.

Daniel J. George, MD, highlights survey findings on the role of caregivers in the treatment journey for patients with metastatic prostate cancer.

In this episode, Adam B. Weiner, MD, sits down with Giorgio Gandaglia, MD, to discuss the ongoing controversy surrounding pelvic lymph node dissection in prostate cancer.

Phase 1 data on 225Ac–J591 showed encouraging antitumor activity with manageable toxicity in patients with mCRPC.

David R. Wise, MD, PhD, discusses the potential for pasritamig combined with docetaxel to improve outcomes in patients with mCRPC.

Robert Flavell, MD, PhD, and Anil P. Bidkar, PhD, discuss the synergistic potential of CD46-directed alpha radiation and ADC therapy combination.

Data from the CANOPY trial showed promising activity and manageable safety with cabozantinib plus nivolumab in mCRPC.

Neha Vapiwala, MD, FASTRO, discusses the integration of radiation therapy with systemic treatment intensification across different stages of localized and locally advanced prostate cancer.

The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of JANX014 in patients with mCRPC.

Fred Saad, MD, FRCS, discusses findings from a post hoc analysis of the phase 3 ARANOTE trial.

Daniel J. George, MD, highlights patient-reported outcomes and tolerability findings from the phase 3 CAPItello-281 trial, evaluating the addition of capivasertib to abiraterone in patients with PTEN-deficient de novo mHSPC.